Boardroom Alpha
Boardroom Alpha
AIRS · Current Report (Form 8-K) · Filed November 18, 2025

Airsculpt Technologies Inc — Current Report (Form 8-K)

Form
8-K
Filed
November 18, 2025
Period
Nov 14, 2025
Ticker
AIRS
Accession
0001104659-25-113294
Boardroom Alpha · Filing insights

AirSculpt appoints Michael Doyle as Class III director and Non-Executive Chairman, effective Nov 14, 2025; he will stand for election at the 2027 annual meeting.

About Airsculpt Technologies Inc
Market cap
$188M
1Y TSR
−44.6%
3Y TSR
−24.0%
Board grade
C
Sector
Healthcare
CEO
Yogesh Jashnani
Last annual meeting: May 12, 2026 · View full Airsculpt Technologies Inc profile →

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2025

 

AirSculpt Technologies, Inc. 

(Exact name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction
of Incorporation)

001-40973

(Commission
File Number)

87-1471855

(IRS Employer
Identification No.
)

     
1111 Lincoln Road, Suite 802
Miami Beach, Florida
 

 

33139

(Address of Principal Executive Offices)   (Zip Code)

 

(786) 709-9690

(Registrant’s Telephone Number, Including Area Code)

 

Not applicable 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:   Trading
Symbol(s):
 

Name of Exchange
on Which Registered:

Common Stock, $0.001 par value per share   AIRS   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 14, 2025, the board of directors (the “Board”) of AirSculpt Technologies, Inc. (the “Company”) elected Michael Doyle to serve as a Class III director of the Board and as the Non-Executive Chairman of the Board, in each case effective as of the same date. Mr. Doyle will stand for election by stockholders at the Company’s 2027 annual meeting of stockholders.

 

Mr. Doyle has served as Managing Partner of Vesey Street Capital Partners since January 2025. Mr. Doyle founded MD Healthcare Partners in 2018 and served as its Chief Executive Officer until December 2024. Previously, Mr. Doyle held several leadership positions, including Chief Executive Officer from 2009 to September 2017, at Surgery Partners (NASDAQ: SGRY), where he led the organization for approximately 15 years and helped to scale it from 3 to over 175 locations. Mr. Doyle has served as Chairman of Orthopedic Solutions Management, a leading orthopedic physician organization, since September 2021, and as Chairman of North America Dental Group since June 2020. He has also served from August 2019 to August 2025 as Chairman of GastroMD, a leading gastroenterologist organization, and from October 2018 to September 2021 as a member of the board of managers of Elite Body Sculpture, the predecessor of the Company prior to its initial public offering.

 

Mr. Doyle will not be compensated for his service as a director and as the Non-Executive Chairman of the Board.

 

There are no arrangements or understandings between Mr. Doyle and any other person pursuant to which he was elected as a director of the Company. There are no family relationships between Mr. Doyle and any other director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Board has determined that Mr. Doyle is an independent director in accordance with the listing requirements of the Nasdaq Global Market.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit No. Description
99.1 Press release dated November 17, 2025
104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 17, 2025    
     
  AirSculpt Technologies, Inc.
     
  By: /s/ Dennis Dean
    Name: Dennis Dean
    Title: Chief Financial Officer

 

[Signature Page to the Form 8-K]

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Airsculpt Technologies Inc (AIRS)

Reference

Frequently asked questions

When did Airsculpt Technologies Inc file this 8-K?
Airsculpt Technologies Inc (AIRS) filed this Current Report (Form 8-K) with the SEC on November 18, 2025. The accession number assigned by EDGAR is 0001104659-25-113294.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
AirSculpt appoints Michael Doyle as Class III director and Non-Executive Chairman, effective Nov 14, 2025; he will stand for election at the 2027 annual meeting. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Airsculpt Technologies Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Airsculpt Technologies Inc has filed under CIK 1870940, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer